Aileron Therapeutics announced that Manuel Aivado, MD, PhD, has been named as President and Chief Executive Officer and elected to its Board of Directors. Since 2012, Dr. Aivado has served as Aileron's Senior Vice President and Chief Medical and Scientific Officer. He succeeds John P. Longenecker, PhD, who was appointed interim CEO on May 15, 2018.

Most recently, Dr. Aivado led Aileron's clinical testing of stapled peptides against intracellular targets and designed and implemented the ALRN-6924 first-in-human trial.